<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="../css/strict.xsl"?>
<PAGE status="unmaintained" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="../css/schema.xsd">
<TITLE>Medical</TITLE>
<PATH>links/medical.xml</PATH>
<DATE><YEAR>2017</YEAR><MONTH>2</MONTH><DAY>5</DAY></DATE>
<CONTENT>
<LLIST>
  <ITEM><SLIST>
    <ITEM><BLIST><TITLE>Regulatory</TITLE>
      <ITEM><BLIST><TITLE><ANCHOR>FDA</ANCHOR><X><T>FDA</T><A>http://www.fda.gov/</A><L>en</L><F>HTML</F></X></TITLE>
        <ITEM><X><T>CDRH</T><A>http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/default.htm</A><L>en</L><F>HTML</F></X></ITEM>
        <ITEM><X><T>510K database</T><A>http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm</A><L>en</L><F>HTML</F></X></ITEM>
        <ITEM><X><T>PMA database</T><A>http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm</A><L>en</L><F>HTML</F></X></ITEM>
        <ITEM><X><T>MAUDE database</T><A>http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.CFM</A><L>en</L><F>HTML</F></X></ITEM>
        <ITEM><X><T>MDR database</T><A>http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMDR/Search.cfm</A><L>en</L><F>HTML</F></X></ITEM>
        <ITEM><X><T>Search CFR Title 21 Database</T><A>http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm</A><L>en</L><F>HTML</F></X></ITEM>
        <ITEM><X><T>warning letters</T><A>http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm</A><L>en</L><F>HTML</F></X></ITEM>
        <ITEM><X><T>personal notes</T><A>../notes/fda.html</A><L>en</L><F>HTML</F></X></ITEM>
      </BLIST></ITEM>
      <ITEM><BLIST><TITLE><ANCHOR>HIPAA</ANCHOR><X><T>HIPAA</T><A>http://aspe.hhs.gov/ADMNSIMP</A><L>en</L><F>HTML</F></X></TITLE>
        <ITEM><X><T>personal notes</T><A>../notes/hipaa.html</A><L>en</L><F>HTML</F></X></ITEM>
      </BLIST></ITEM>
      <ITEM><BLIST><TITLE><X><T>CFR</T><A>http://www.access.gpo.gov/nara/cfr/cfr-table-search.html</A><L>en</L><F>HTML</F></X></TITLE>
        <ITEM><X><T>21 CFR Part 11</T><A>http://www.gpo.gov/fdsys/pkg/CFR-2007-title21-vol1/content-detail.html</A><L>en</L><F>HTML</F></X>
        (<X><T>21cfrpart11.com</T><A>http://www.21cfrpart11.com</A><L>en</L><F>HTML</F></X>)</ITEM>
      </BLIST></ITEM>
    </BLIST></ITEM>
    <ITEM><CLIST><TITLE>EHR</TITLE>
      <ITEM><X><T>EHRVA</T><A>http://www.himssehra.org</A><L>en</L><F>HTML</F></X></ITEM>
    </CLIST></ITEM>
    <ITEM><BLIST><TITLE>HL7</TITLE>
      <ITEM><X><T>hl7.org</T><A>http://www.hl7.org</A><L>en</L><F>HTML</F></X></ITEM>
      <ITEM><X><T>FAQ</T><A>http://www.hl7.org/about/HL7FAQ.cfm</A><L>en</L><F>HTML</F></X></ITEM>
      <ITEM>CCOW:
        <X><T>HL7 CCOW</T><A>http://www.hl7.org/special/Committees/ccow_sigvi.htm</A><L>en</L><F>HTML</F></X>
      </ITEM>
    </BLIST></ITEM>
    <ITEM><CLIST><TITLE>news</TITLE>
      <ITEM><X><T>Reuters</T><A>http://www.reutershealth.com/</A><L>en</L><F>HTML</F></X></ITEM>
      <ITEM><X><T>LinuxMedNews</T><A>http://www.linuxmednews.com/</A><L>en</L><F>HTML</F></X></ITEM>
      <ITEM><X><T>Health Industry Insights</T><A>http://www.healthindustry-insights.com</A><L>en</L><F>HTML</F></X>
        (<X><T>newsletter</T><A>http://www.idc.com/downloads/HealthInsightsOutlooks.pdf</A><L>en</L><F>PDF</F></X>)</ITEM>
    </CLIST></ITEM>
    <ITEM><CLIST><TITLE>open source</TITLE>
      <ITEM><X><T>Wikipedia</T><A>http://en.wikipedia.org/wiki/List_of_open_source_healthcare_software</A><L>fr</L><F>HTML</F></X></ITEM>
    </CLIST></ITEM>
    <ITEM><X><T>Le R&#xE9;seau Sant&#xE9; Social</T><A>http://www.cegetel.rss.fr</A><L>fr</L><F>HTML</F></X></ITEM>
    <ITEM><X><T>Centrale-Sant&#xE9;</T><A>http://www.centrale-sante.net</A><L>fr</L><F>HTML</F></X></ITEM>
    <ITEM><X><T>The Laszlo Letter</T><A>http://laszloletter.typepad.com</A><L>fr</L><F>HTML</F></X></ITEM>
  </SLIST></ITEM>
  <ITEM><BLIST><TITLE>Articles</TITLE>
    <ITEM><BLIST><TITLE>FDA</TITLE>
      <ITEM><BLIST><TITLE>Regulations and guidelines</TITLE>
        <ITEM><ARTICLE><X><T>Guidance for Industry - Part 11, Electronic Records; Electronic Signatures - Scope and Application</T><A>http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126953.pdf</A><L>en</L><F>PDF</F></X><DATE><YEAR>2003</YEAR><MONTH>8</MONTH></DATE><COMMENT>The FDA guidance for applying 21 CFR Part 11.</COMMENT></ARTICLE></ITEM>
        <ITEM><BLIST><TITLE>Medical devices</TITLE>
          <ITEM><ARTICLE><X><T>Deciding When to Submit a 510(k) for a Change to an Existing Device</T><A>http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm073658.pdf</A><L>en</L><F>PDF</F></X><X><T>Deciding When to Submit a 510(k) for a Change to an Existing Device</T><A>http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm073655.htm</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Susan</FIRSTNAME><LASTNAME>Alpert</LASTNAME></AUTHOR><DATE><YEAR>1997</YEAR><MONTH>1</MONTH><DAY>10</DAY></DATE><COMMENT>The title says everything.</COMMENT></ARTICLE></ITEM>
          <ITEM><ARTICLE><X><T>Guidance for Industry, FDA Reviewers and Compliance on Off-The-Shelf Software Use in Medical Devices</T><A>http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm073779.pdf</A><L>en</L><F>PDF</F></X><AUTHOR><FIRSTNAME>Donna-Bea</FIRSTNAME><LASTNAME>Tillman</LASTNAME></AUTHOR><DATE><YEAR>1999</YEAR><MONTH>9</MONTH><DAY>9</DAY></DATE><COMMENT>The FDA guidance for systems containing OTS software.</COMMENT></ARTICLE></ITEM>
          <ITEM><ARTICLE><X><T>Guidance for Industry - Cybersecurity for Networked Medical Devices Containing Off-the-Shelf (OTS) Software</T><A>http://www.21cfrpart11.com/files/library/reg_guid_docs/networkedeviceswithotssotfware.pdf</A><L>en</L><F>PDF</F></X><AUTHOR><FIRSTNAME>John</FIRSTNAME><MIDDLENAME>F.</MIDDLENAME><LASTNAME>Murray</LASTNAME><NAMESUFFIX>Jr.</NAMESUFFIX></AUTHOR><AUTHOR><FIRSTNAME>David</FIRSTNAME><MIDDLENAME>S.</MIDDLENAME><LASTNAME>Buckles</LASTNAME></AUTHOR><DATE><YEAR>2005</YEAR><MONTH>1</MONTH><DAY>14</DAY></DATE><COMMENT>The FDA guidance for handling security patches of off-the-shelf components.</COMMENT></ARTICLE></ITEM>
          <ITEM><ARTICLE><X><T>General Principles of Software Validation; Final Guidance for Industry and FDA Staff</T><A>http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm085371.pdf</A><L>en</L><F>PDF</F></X><X><T>General Principles of Software Validation; Final Guidance for Industry and FDA Staff</T><A>http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm085281.htm</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>John</FIRSTNAME><MIDDLENAME>F.</MIDDLENAME><LASTNAME>Murray</LASTNAME><NAMESUFFIX>Jr.</NAMESUFFIX></AUTHOR><AUTHOR><FIRSTNAME>Jerome</FIRSTNAME><LASTNAME>Davis</LASTNAME></AUTHOR><DATE><YEAR>2002</YEAR><MONTH>1</MONTH><DAY>11</DAY></DATE><COMMENT>The title says all.</COMMENT></ARTICLE></ITEM>
        <ITEM><ARTICLE><X><T>Medical Device Quality Systems Manual: A Small Entity Compliance Guide</T><A>http://www.gmp-compliance.org/guidemgr/files/MDQS.MANUAL.PDF</A><L>en</L><F>PDF</F></X><DATE><YEAR>1996</YEAR><MONTH>12</MONTH></DATE><COMMENT>A guide for a small company's Quality System.</COMMENT></ARTICLE></ITEM>
          <ITEM><ARTICLE><X><T>Design Control Guidance For Medical Device Manufacturers -- This Guidance relates to FDA 21 CFR 820.30 and Sub-clause 4.4 of ISO 9001</T><A>http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070642.pdf</A><L>en</L><F>PDF</F></X><X><T>Design Control Guidance For Medical Device Manufacturers -- This Guidance relates to FDA 21 CFR 820.30 and Sub-clause 4.4 of ISO 9001</T><A>http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm070627.htm</A><L>en</L><F>HTML</F></X><DATE><YEAR>1997</YEAR><MONTH>3</MONTH><DAY>11</DAY></DATE><COMMENT>This guideline explains what are design controls.</COMMENT></ARTICLE></ITEM>
        </BLIST></ITEM>
        <ITEM><BLIST><TITLE>Clinical trials</TITLE>
          <ITEM><ARTICLE><X><T>Guidance for Industry - Computerized Systems Used in Clinical Investigations</T><A>http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070266.pdf</A><L>en</L><F>PDF</F></X><DATE><YEAR>2007</YEAR><MONTH>5</MONTH></DATE><COMMENT>The title says all.</COMMENT></ARTICLE></ITEM>
          <ITEM><ARTICLE><X><T>Guidance for Industry Providing Regulatory Submissions in Electronic Format - Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications</T><A>http://www.fda.gov/RegulatoryInformation/Guidances/ucm126959.htm</A><L>en</L><F>PDF</F></X><DATE><YEAR>2006</YEAR><MONTH>4</MONTH></DATE><COMMENT>The FDA guidance for clinical trials submissions.</COMMENT></ARTICLE></ITEM>
          <ITEM><ARTICLE><X><T>Guidance for Industry - Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics</T><A>http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf</A><L>en</L><F>PDF</F></X><DATE><YEAR>2007</YEAR><MONTH>5</MONTH></DATE><COMMENT>The title says all.</COMMENT></ARTICLE></ITEM>
        </BLIST></ITEM>
      </BLIST></ITEM>
      <ITEM><BLIST><TITLE>Warning Letters</TITLE>
        <ITEM><ARTICLE><X><T>Warning Letter: Rosenthal, Kenneth J., M.D. 11-Apr-05</T><A>http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2005/ucm075362.htm</A><L>en</L><F>HTML</F></X><DATE><YEAR>2005</YEAR><MONTH>4</MONTH><DAY>11</DAY></DATE><COMMENT>The investigator failed to maintain adequate records, to respect the protocol agreement, and to provide reports to the IRB&#x2026;</COMMENT></ARTICLE></ITEM>
      </BLIST></ITEM>
      <ITEM><BLIST><TITLE>Application of FDA rules</TITLE>
        <ITEM><ARTICLE><X><T>Advantages to Risk-Based Validation</T><ST>How to decrease computer-system validation time and costs</ST><A>http://qualitydigest.com/IQedit/QDarticle_text.lasso?articleid=12743</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>David</FIRSTNAME><LASTNAME>Ade</LASTNAME></AUTHOR><DATE><YEAR>2008</YEAR><MONTH>5</MONTH></DATE><COMMENT>The FDA advocates a risk-based validation strategy.</COMMENT></ARTICLE></ITEM>
      </BLIST></ITEM>
      <ITEM><BLIST><TITLE>Janus</TITLE>
        <ITEM><ARTICLE><X><T>JanusDDQBDemo2</T><A>http://realmedia.nci.nih.gov:8080/ramgen/CRIX/JanusDDQBDemo2.rm</A><L>en</L><F>RealMedia</F><DURATION><MINUTE>15</MINUTE><SECOND>24</SECOND></DURATION></X><DATE><YEAR>2006</YEAR></DATE><COMMENT>A demo of IBM's DDQB (Data Discovery and Query Builder) on <X><T>Janus</T><A>http://crix.nci.nih.gov/projects/janus/</A><L>en</L><F>HTML</F></X>.</COMMENT></ARTICLE></ITEM>
        <ITEM><ARTICLE><X><T>JanuscaCOREPrototypeDemo</T><A>http://realmedia.nci.nih.gov:8080/ramgen/CRIX/JanuscaCOREPrototypeDemo.rm</A><L>en</L><F>RealMedia</F><DURATION><MINUTE>19</MINUTE><SECOND>41</SECOND></DURATION></X><DATE><YEAR>2006</YEAR></DATE><COMMENT>A demo of caCORE on Janus.</COMMENT></ARTICLE></ITEM>
      </BLIST></ITEM>
      <ITEM><BLIST><TITLE>Evolution</TITLE>
        <ITEM><ARTICLE><X protection='free_registration'><T>U.S. FDA to add 1,300 staffers in big expansion</T><A>http://www.auntminnie.com/index.asp?Sec=nws&amp;Sub=rad&amp;Pag=dis&amp;ItemId=80942</A><L>en</L><F>HTML</F></X><DATE><YEAR>2008</YEAR><MONTH>8</MONTH><DAY>1</DAY></DATE><COMMENT>FDA will hire 1300 persons, mainly for drug approval and postmarket vigilance.</COMMENT></ARTICLE></ITEM>
        <ITEM><ARTICLE><X><T>Sentinel Initiative Boosts FDA Safety Oversight</T><A>http://www.bio-itworld.com/ecliniqua/2008/10/06/sentinel-initiative.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Ann</FIRSTNAME><LASTNAME>Neuer</LASTNAME></AUTHOR><DATE><YEAR>2008</YEAR><MONTH>10</MONTH><DAY>6</DAY></DATE><COMMENT>The FDA tries to create a tool for monitoring marketed medical products.</COMMENT></ARTICLE></ITEM>
        <ITEM><ARTICLE><X><T>eCTD: The First Nine Months</T><A>http://www.bio-itworld.com/issues/2008/sept/ectd-implementation.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Ann</FIRSTNAME><LASTNAME>Neuer</LASTNAME></AUTHOR><DATE><YEAR>2008</YEAR><MONTH>9</MONTH><DAY>5</DAY></DATE><COMMENT>Still many eCTD submissions are improperly filled.</COMMENT></ARTICLE></ITEM>
        <ITEM><ARTICLE><X><T>Trials Disclosure Clears Next FDAAA Deadline</T><A>http://www.bio-itworld.com/ecliniqua/2008/10/27/clinical-trials-disclosure.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Deborah</FIRSTNAME><LASTNAME>Borfitz</LASTNAME></AUTHOR><DATE><YEAR>2008</YEAR><MONTH>10</MONTH><DAY>27</DAY></DATE><COMMENT>Sponsors have now to report basic results on clinicaltrials.gov. Next year, they will also have to report adverse events.</COMMENT></ARTICLE></ITEM>
      </BLIST></ITEM>
      <ITEM><BLIST><TITLE>Controversies</TITLE>
        <ITEM><ARTICLE><X><T>New FDA Research Center Rife With Risks</T><A>http://newsok.com/new-fda-research-center-rife-with-risks/article/3148494</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Matthew</FIRSTNAME><LASTNAME>Perrone</LASTNAME></AUTHOR><DATE><YEAR>2007</YEAR><MONTH>10</MONTH><DAY>14</DAY></DATE><COMMENT>The creation of the Reagan-Udall Foundation and the issue of the FDA independence from the pharma industry.</COMMENT></ARTICLE></ITEM>
        <ITEM><ARTICLE><X><T>Independent Testing and the FDA</T><A>http://qualitydigest.com/IQedit/QDarticle_text.lasso?articleid=12658</A><L>en</L><F>HTML</F></X><DATE><YEAR>2008</YEAR><MONTH>1</MONTH><DAY>30</DAY></DATE><COMMENT>The FDA review process is not properly done for medical devices, a review by an independent organization may compensate this.</COMMENT></ARTICLE></ITEM>
        <ITEM><ARTICLE><X><T>FDA denies it is risk-averse on drugs</T><A>http://www.ft.com/cms/s/0/7ae3646a-fad6-11dc-aa46-000077b07658.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Andrew</FIRSTNAME><LASTNAME>Jack</LASTNAME></AUTHOR><DATE><YEAR>2008</YEAR><MONTH>3</MONTH><DAY>26</DAY></DATE><COMMENT>Janet Woodcock, the head of CDER, denies that FDA is too afraid of taking risks when evaluating new drugs.</COMMENT></ARTICLE></ITEM>
        <ITEM><ARTICLE><X><T>FDA, Facing Criticism, Bars Doctors From Drug Trials</T><A>http://www.bloomberg.com/apps/news?pid=newsarchive&amp;sid=agWbmNWCYwIY</A><L>en</L><F>HTML</F></X><DATE><YEAR>2008</YEAR><MONTH>6</MONTH><DAY>6</DAY></DATE><COMMENT>FDA tries to be more effective at disallowing wrong-doing investigators to participate to other clinical trials.</COMMENT></ARTICLE></ITEM>
        <ITEM><ARTICLE><X protection='free_registration'><T>FDA clears cardio devices on weak research - study</T><A>http://www.auntminnie.com/index.asp?Sec=sup&amp;Sub=car&amp;Pag=dis&amp;ItemId=88966</A><L>en</L><F>HTML</F></X><DATE><YEAR>2009</YEAR><MONTH>12</MONTH><DAY>30</DAY></DATE><COMMENT>Does the FDA approve too easily some medical devices?</COMMENT></ARTICLE></ITEM>
      </BLIST></ITEM>
    </BLIST></ITEM>
    <ITEM><BLIST><TITLE>HIPAA</TITLE>
      <ITEM><ARTICLE><X><T>Protecting The Privacy of Patients' Health Information - Summary of The Final Regulation</T><A>http://aspe.hhs.gov/admnsimp/final/pvcfact1.htm</A><L>en</L><F>HTML</F></X><DATE><YEAR>2000</YEAR><MONTH>12</MONTH><DAY>20</DAY></DATE><COMMENT>An overview (from the patient's point of view) of HIPAA.</COMMENT></ARTICLE></ITEM>
      <ITEM><ARTICLE><X><T>What takes precedence: HIPAA or state law?</T><ST>In most cases, state laws will not be preempted by HIPAA</ST><A>http://www.apa.org/monitor/jan03/hipaa.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Jennifer</FIRSTNAME><MIDDLENAME>Daw</MIDDLENAME><LASTNAME>Holloway</LASTNAME></AUTHOR><DATE><YEAR>2003</YEAR><MONTH>1</MONTH></DATE><COMMENT>The most stringent law will have to be applied: HIPAA if it is more protective of patient's privacy than the state law, the state law otherwise.</COMMENT></ARTICLE></ITEM>
      <ITEM><ARTICLE><X><T>More protections for patients and psychologists under HIPAA</T><ST>HIPAA's psychotherapy notes provision safeguards sensitive patient information</ST><A>http://www.apa.org/monitor/feb03/hipaa.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Jennifer</FIRSTNAME><MIDDLENAME>Daw</MIDDLENAME><LASTNAME>Holloway</LASTNAME></AUTHOR><DATE><YEAR>2003</YEAR><MONTH>2</MONTH></DATE><COMMENT>The author describes how HIPAA applies to psychotherapy notes.</COMMENT></ARTICLE></ITEM>
      <ITEM><ARTICLE><X><T>Peddicord: New Privacy Concerns with &#x2018;HIPAA 2&#x2019;</T><A>http://www.ecliniqua.com/2010/1/4/hipaa2.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Deborah</FIRSTNAME><LASTNAME>Borfitz</LASTNAME></AUTHOR><DATE><YEAR>2010</YEAR><MONTH>1</MONTH><DAY>4</DAY></DATE><COMMENT>Some new privacy and security requirements are part of American Recovery and Reinvestment Act.</COMMENT></ARTICLE></ITEM>
      <ITEM><ARTICLE><X><T>The Reality of Medical Software Compliance</T><A>http://www.ecliniqua.com/2010/01/19/sagekey.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Kent</FIRSTNAME><LASTNAME>Matthies</LASTNAME></AUTHOR><DATE><YEAR>2010</YEAR><MONTH>1</MONTH><DAY>19</DAY></DATE><COMMENT>Some advice to healthcare providers in order to be compliant with the HITECH Act.</COMMENT></ARTICLE></ITEM>
    </BLIST></ITEM>
    <ITEM><BLIST><TITLE>China</TITLE>
      <ITEM><ARTICLE><X><T>Ex-Chief of China Food and Drug Unit Sentenced to Death for Graft</T><A>http://www.nytimes.com/2007/05/30/world/asia/30china.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>David</FIRSTNAME><LASTNAME>Barboza</LASTNAME></AUTHOR><DATE><YEAR>2007</YEAR><MONTH>5</MONTH><DAY>30</DAY></DATE><COMMENT>China's FDA chief gets sentenced to death penalty for accepting some bribes!</COMMENT></ARTICLE></ITEM>
    </BLIST></ITEM>
    <ITEM><BLIST><TITLE>India</TITLE>
      <ITEM><ARTICLE><X><T>Regulatory Changes Afoot in India</T><A>http://www.bio-itworld.com/ecliniqua/2008/11/24/regulatory-changes-in-india.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Deborah</FIRSTNAME><LASTNAME>Borfitz</LASTNAME></AUTHOR><DATE><YEAR>2008</YEAR><MONTH>11</MONTH><DAY>24</DAY></DATE><COMMENT>India will change its regulations for phase 1 clinical tests of molecules created in other countries</COMMENT></ARTICLE></ITEM>
    </BLIST></ITEM>
    <ITEM><BLIST><TITLE>Electronic health record</TITLE>
      <ITEM><ARTICLE><X><T>Visualizing Electronic Health Records With "Google-Earth for the Body"</T><A>http://www.spectrum.ieee.org/jan08/5854</A><L>en</L><F>HTML</F></X><DATE><YEAR>2008</YEAR><MONTH>1</MONTH></DATE><COMMENT>IBM has created a 3D visualization to help navigate the patient's EHR.</COMMENT></ARTICLE></ITEM>
    </BLIST></ITEM>
    <ITEM><BLIST><TITLE>Personal health record</TITLE>
      <ITEM><ARTICLE><X><T>New Frontiers in PHRs</T><A>http://www.bio-itworld.com/DigitalHealthCare_Article.aspx?id=81582</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Stephen</FIRSTNAME><LASTNAME>Barlas</LASTNAME></AUTHOR><DATE><YEAR>2008</YEAR><MONTH>9</MONTH><DAY>23</DAY></DATE><COMMENT>The PHR market is taking off.</COMMENT></ARTICLE></ITEM>
    </BLIST></ITEM>
    <ITEM><BLIST><TITLE>Genomics</TITLE>
      <ITEM><ARTICLE><X><T>Predicting Dose Response</T><A>http://www.bio-itworld.com/issues/2007/sept/first-base/</A><L>en</L><F>HTML</F></X><DATE><YEAR>2007</YEAR><MONTH>9</MONTH><DAY>13</DAY></DATE><COMMENT>Genetic testing would help dosing warfarin.</COMMENT></ARTICLE></ITEM>
      <ITEM><ARTICLE><X><T>FDA Warms to Pathway Tool Use</T><A>http://www.bio-itworld.com/issues/2008/may/russell-transcript-fda-vgds-program.html</A><L>en</L><F>HTML</F></X><DATE><YEAR>2008</YEAR><MONTH>5</MONTH><DAY>12</DAY></DATE><COMMENT>FDA expects that its VXDS (Voluntary Exploratory Data Submissions), after being successful with microarray processing techniques, will give similar results with pathway tools.</COMMENT></ARTICLE></ITEM>
      <ITEM><ARTICLE><X><T>The DNA Data Deluge</T><A>http://www.bio-itworld.com/issues/2008/april/cover-story-dna-data-deluge.html/</A><L>en</L><F>HTML</F></X><DATE><YEAR>2008</YEAR><MONTH>4</MONTH><DAY>1</DAY></DATE><COMMENT>DNA sequencing is generating huge amounts of data, how can this data be managed?</COMMENT></ARTICLE></ITEM>
      <ITEM><ARTICLE><X><T>You've Got Email</T><ST>A Human Genome</ST><A>http://www.bio-itworld.com/news/2009/01/30/Email-compression-genome.html/</A><L>en</L><F>HTML</F></X><DATE><YEAR>2009</YEAR><MONTH>1</MONTH><DAY>30</DAY></DATE><COMMENT>Genome sequences can be better compressed by recording only the differences to a reference genome.</COMMENT></ARTICLE></ITEM>
      <ITEM><ARTICLE><X><T>Eric Lander Reviews &#x201C;Breathtaking&#x201D; Advances in Genome Sequencing</T><A>http://www.bio-itworld.com/news/02/05/09/lander-advances-genome-sequencing-AGBT.html</A><L>en</L><F>HTML</F></X><DATE><YEAR>2009</YEAR><MONTH>2</MONTH><DAY>5</DAY></DATE><COMMENT>Eric Lander speech on the future of sequencing.</COMMENT></ARTICLE></ITEM>
      <ITEM><ARTICLE><X><T>Pinpointing a Perfect Pitch Gene</T><A>http://www.bio-itworld.com/news/08/13/09/pinpointing-perfect-pitch-gene.html</A><L>en</L><F>HTML</F></X><DATE><YEAR>2009</YEAR><MONTH>8</MONTH><DAY>13</DAY></DATE><COMMENT>Jane Gitschier is looking for the absolute pitch gene.</COMMENT></ARTICLE></ITEM>
      <ITEM><ARTICLE><X quality ='-1'><T>The Genome Question: Moore vs. Jevons with Bud Mishra</T><A>https://www.youtube.com/watch?v=VWePa16iX20</A><L>en</L><F>Flash Video</F><DURATION><HOUR>1</HOUR><MINUTE>18</MINUTE><SECOND>54</SECOND></DURATION></X><AUTHOR><FIRSTNAME>Bud</FIRSTNAME><LASTNAME>Mishra</LASTNAME></AUTHOR><DATE><YEAR>2012</YEAR><MONTH>3</MONTH><DAY>27</DAY></DATE><COMMENT>The issue of the data deluge, the fact that genomics failed to deliver what we expected from it, and some proposed solutions.</COMMENT></ARTICLE></ITEM>
      <ITEM><ARTICLE><X><T>Human Genetics and Genomics: The Science for the 21st Century</T><A>https://www.youtube.com/watch?v=9SzwiZMSBeQ</A><L>en</L><F>Flash Video</F><DURATION><MINUTE>56</MINUTE><SECOND>45</SECOND></DURATION></X><AUTHOR><FIRSTNAME>Ewan</FIRSTNAME><LASTNAME>Birney</LASTNAME></AUTHOR><DATE><YEAR>2012</YEAR><MONTH>7</MONTH><DAY>12</DAY></DATE><COMMENT>A presentation trying to motivate software engineers to work in the field of genomics.</COMMENT></ARTICLE></ITEM>
      <ITEM><BLIST><TITLE>Personal genomics</TITLE>
        <ITEM><ARTICLE><X><T>Personal Genomics Companies Rush to Comply with California Regulations</T><A>http://www.bio-itworld.com/personal-genomics-companies-rush-to-comply.html</A><L>en</L><F>HTML</F></X><DATE><YEAR>2008</YEAR><MONTH>6</MONTH><DAY>18</DAY></DATE><COMMENT>Regulators are looking to personal genomics companies.</COMMENT></ARTICLE></ITEM>
        <ITEM><BLIST><TITLE>23andMe</TITLE>
          <ITEM><ARTICLE><X><T>23andMe: Avey Proposes New Personal Genomics Paradigm</T><A>http://www.bio-itworld.com/headlines/2008/05/avey-keynote-bitw-expo.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Kevin</FIRSTNAME><LASTNAME>Davies</LASTNAME></AUTHOR><DATE><YEAR>2008</YEAR><MONTH>5</MONTH><DAY>13</DAY></DATE><COMMENT>A summary of Linda Avey, co-founder of 23andMe, presentation of her company at Bio-IT World Expo.</COMMENT></ARTICLE></ITEM>
          <ITEM><ARTICLE><X><T>Googling the Googlers' DNA: A Demonstration of the 23andMe Personal Genome Service Using Three Relatively Well Known Googlers as Illustrative Examples</T><A>https://www.youtube.com/watch?v=aeF-0y9HP9A</A><L>fr</L><F>Flash Video</F><DURATION><MINUTE>53</MINUTE><SECOND>29</SECOND></DURATION></X><AUTHOR><FIRSTNAME>Linda</FIRSTNAME><LASTNAME>Avey</LASTNAME></AUTHOR><DATE><YEAR>2008</YEAR><MONTH>5</MONTH><DAY>7</DAY></DATE><COMMENT>This presentation seems to be the same as the one reported in the previous article.</COMMENT></ARTICLE></ITEM>
        </BLIST></ITEM>
        <ITEM><BLIST><TITLE>deCODEme</TITLE>
          <ITEM><ARTICLE><X><T>Software Glitch Scrambles Personal Genomics Data</T><A>http://www.bio-itworld.com/news/08/27/09/software-glitch-scrambles-personal-genomics-data.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Kevin</FIRSTNAME><LASTNAME>Davies</LASTNAME></AUTHOR><DATE><YEAR>2009</YEAR><MONTH>8</MONTH><DAY>27</DAY></DATE><COMMENT>A journalist found a bug in deCODEme presentation software.</COMMENT></ARTICLE></ITEM>
        </BLIST></ITEM>
      </BLIST></ITEM>
    </BLIST></ITEM>
    <ITEM><BLIST><TITLE>HL7</TITLE>
      <ITEM><ARTICLE><X><T>HL7 101: A Beginner&#x2019;s Guide</T><A>http://www.fortherecordmag.com/archives/ftr_01082007p22.shtml</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Dave</FIRSTNAME><LASTNAME>Shaver</LASTNAME></AUTHOR><DATE><YEAR>2007</YEAR><MONTH>2</MONTH><DAY>26</DAY></DATE><COMMENT>A high level introduction to HL7 history and purpose.</COMMENT></ARTICLE></ITEM>
      <ITEM><ARTICLE><X><T>HL7 RIM: An Incoherent Standard</T><A>http://ontology.buffalo.edu/hl7/doublestandards.pdf</A><L>en</L><F>PDF</F></X><AUTHOR><FIRSTNAME>Barry</FIRSTNAME><LASTNAME>Smith</LASTNAME></AUTHOR><AUTHOR><FIRSTNAME>Werner</FIRSTNAME><LASTNAME>Ceusters</LASTNAME></AUTHOR><DATE><YEAR>2006</YEAR><MONTH>8</MONTH></DATE><COMMENT>The authors criticize RIM for mixing the information model (how the IT models the healthcare world) and a reference ontology (the model of the healthcare world itself).</COMMENT></ARTICLE></ITEM>
      <ITEM><ARTICLE><X><T>The HL7 Reference Information Model Under Scrutiny</T><A>http://amisha.pragmaticdata.com/~schadow/Schadow-MIE06-r3.pdf</A><L>en</L><F>PDF</F></X><AUTHOR><FIRSTNAME>Gunther</FIRSTNAME><LASTNAME>Schadow</LASTNAME></AUTHOR><AUTHOR><FIRSTNAME>Charles</FIRSTNAME><MIDDLENAME>N.</MIDDLENAME><LASTNAME>Mead</LASTNAME></AUTHOR><AUTHOR><FIRSTNAME>D.</FIRSTNAME><MIDDLENAME>Mead</MIDDLENAME><LASTNAME>Walker</LASTNAME></AUTHOR><DATE><YEAR>2006</YEAR></DATE><COMMENT>The authors answer to several criticisms on RIM: RIM violated UML; the information model / reference ontology mix (this is the previous article); speech acts not encoding the act itself, being attributed, and having no "continuants".</COMMENT></ARTICLE></ITEM>
    </BLIST></ITEM>
    <ITEM><ARTICLE><X><T>Fed up hospitals defy patching rules</T><A>http://www.networkworld.com/news/2004/080904patchfights.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Ellen</FIRSTNAME><LASTNAME>Messmer</LASTNAME></AUTHOR><DATE><YEAR>2004</YEAR><MONTH>7</MONTH><DAY>9</DAY></DATE><COMMENT>Hospitals are angry to wait a long time for medical manufacturers to validate their software against the latest OS security patches.</COMMENT></ARTICLE></ITEM>
    <ITEM><ARTICLE><X><T>Custom Solution Connects Doctors and Patient Data</T><A>http://www.bio-itworld.com/2008/11/24/project-echo.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Allison</FIRSTNAME><LASTNAME>Proffitt</LASTNAME></AUTHOR><DATE><YEAR>2008</YEAR><MONTH>11</MONTH><DAY>24</DAY></DATE><COMMENT>A project for collecting hepatitis C data in New Mexico is based on highly customisable forms so any participant can adapt the tool to his own needs.</COMMENT></ARTICLE></ITEM>
    <ITEM><ARTICLE><X protection='free_registration'><T>CT screening flap leads to change in NEJM disclosure policy</T><A>http://www.auntminnie.com/index.asp?Sec=sup&amp;Sub=cto&amp;Pag=dis&amp;ItemId=84223</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Eric</FIRSTNAME><LASTNAME>Barnes</LASTNAME></AUTHOR><DATE><YEAR>2003</YEAR><MONTH>1</MONTH><DAY>13</DAY></DATE><COMMENT>The New England Journal of Medicine asks authors to reveal potential conflicts of interests.</COMMENT></ARTICLE></ITEM>
    <ITEM><ARTICLE><X protection ='payed_registration'><T>Twittering Healthcare: Social Media and Medicine</T><A>http://www.liebertonline.com/doi/pdf/10.1089/tmj.2009.9955</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Mark</FIRSTNAME><LASTNAME>Terry</LASTNAME></AUTHOR><DATE><YEAR>2009</YEAR><MONTH>8</MONTH></DATE><COMMENT>Some uses of Twitter for healthcare: physicians, hospitals, TrialX and CDC.</COMMENT></ARTICLE></ITEM>
    <ITEM><ARTICLE><X><T>Patent Rights and Civil Wrongs: The ACLU Lawsuit</T><A>http://www.bio-itworld.com/comment/2009/07/06/ACLU-lawsuit.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Andrew</FIRSTNAME><MIDDLENAME>W.</MIDDLENAME><LASTNAME>Torrance</LASTNAME></AUTHOR><DATE><YEAR>2009</YEAR><MONTH>6</MONTH><DAY>6</DAY></DATE><COMMENT>The ACLU challenges the fact that human genes and diagnostic methods are patentable.</COMMENT></ARTICLE></ITEM>
    <ITEM><ARTICLE><X><T>The Theranos Scandal Is Just The Beginning</T><ST>There will be more companies like Theranos in our future.</ST><A>http://www.fastcompany.com/3059230/the-theranos-scandal-is-just-the-beginning</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Christina</FIRSTNAME><LASTNAME>Farr</LASTNAME></AUTHOR><DATE><YEAR>2016</YEAR><MONTH>5</MONTH><DAY>10</DAY></DATE><COMMENT>Investors, who have no clue about biotech, will continue to dumbly put money in dubious startups.</COMMENT></ARTICLE></ITEM>
  </BLIST></ITEM>
</LLIST>
</CONTENT>
<X><T>health information</T><A>../links/health.html</A><L>en</L><F>HTML</F></X>
</PAGE>
